Key Insights

Highlights

Treatment Research

4 treatments under study, led by Carboplatin

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00955305Phase 2Terminated

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Carboplatin1
  • Paclitaxel1
  • Cixutumumab1
  • Bevacizumab1

Active Sponsors

  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Stage Iv Nonsmall Cell Lung Cancer1
  • Lung Adenocarcinoma1
  • Recurrent Nonsmall Cell Lung Carcinoma1
  • Large Cell Lung Carcinoma1

Activity Timeline